Metasyn joins forces with Daiichi

Article

Contrast developer Metasyn has signed a $12 million agreementwith Daiichi Radioisotope Laboratories of Tokyo for Japanese developmentand marketing of MS-325, Metasyn's vascular MRI contrast agent.Under the agreement, Metasyn will receive $12 million in

Contrast developer Metasyn has signed a $12 million agreement

with Daiichi Radioisotope Laboratories of Tokyo for Japanese development

and marketing of MS-325, Metasyn's vascular MRI contrast agent.

Under the agreement, Metasyn will receive $12 million in license

fees, milestone payments, and an equity investment, in addition

to royalties on sales of the product. Daiichi will be responsible

for clinical development, registration, and commercialization

of MS-325 in Japan. Metasyn, of Cambridge, MA, will manufacture

MS-325 for Daiichi and will retain rights to the product outside

Japan. Metasyn expects to begin clinical trials of the agent in

the U.S. this year.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.